Our research focus lies on the expression, regulation, functional role and therapeutic potential of HIF Prolyl Hydroxylases in the kidney. Prolyl Hydroxylases hydroxylate the transcription factor Hypoxia Inducible Factor which controls numerous potentially nephroprotective target genes. When hydroxylation is inhibited, HIF is stabilized in the cell and induces its target genes. In order to inhibit the Prolyl Hydroxylases we use transgenic models of tubular HIF stabilization and new experimental pharmacological substances, which are able to stabilize HIF in the cell. In particular we aim to contribute to develop new therapeutic strategies for acute kidney injury.